Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
Clinical trial NCT04210843 · TERMINATED
Trial details
- NCT number
- NCT04210843
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-08
- Primary completion
- 2022-09-01
- Enrollment
- 1033
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.